The most common Ozempic side effects are gastrointestinal: nausea (affecting ~20% of patients), diarrhea, vomiting, and constipation. These typically occur during dose titration and improve within weeks. Serious side effects are rare but include pancreatitis and gallbladder issues. Since Ozempic and Wegovy contain the same semaglutide, their side effect profiles are essentially identical.
Ozempic (semaglutide) is FDA-approved for type 2 diabetes, not weight loss. For weight management, the same molecule is available as Wegovy, which is FDA-approved for chronic weight management. At PEAK, we prescribe Wegovy for weight-loss patients.
Common side effects
Most Ozempic side effects are gastrointestinal and dose-related. They’re most noticeable during the titration period (when doses are being increased) and tend to diminish as your body adjusts:
- Nausea — the most frequently reported side effect (~20% of patients). Usually mild to moderate and peaks during the first few weeks at each new dose level.
- Diarrhea — affects approximately 8–10% of patients. Typically transient.
- Vomiting — less common than nausea (~5–8%). More likely at higher doses or with rapid titration.
- Constipation — affects some patients as semaglutide slows gastric motility.
- Abdominal pain — usually mild, related to changes in digestion speed.
- Decreased appetite — this is the therapeutic effect, but some patients experience it as an unwanted intensity of appetite suppression.
- Injection site reactions — mild redness or irritation at the injection site. Uncommon with proper technique.
Serious side effects (rare)
These are uncommon but require medical attention:
- Pancreatitis. Severe abdominal pain radiating to the back. Discontinue and contact your clinician immediately.
- Gallbladder disease. Rapid weight loss can increase gallstone risk. Report persistent right-upper-quadrant pain.
- Thyroid tumors. Semaglutide carries a boxed warning for medullary thyroid carcinoma (MTC) risk based on rodent studies. Patients with personal or family history of MTC or MEN 2 should not use semaglutide.
- Hypoglycemia. Rare when used alone; risk increases with concurrent insulin or sulfonylureas.
- Kidney injury. Severe dehydration from GI side effects can affect kidney function. Staying hydrated is important.
- Allergic reactions. Very rare. Symptoms include swelling, difficulty breathing, or severe rash.
Managing side effects
Most GI side effects can be minimized with these clinician-recommended strategies:
- Slow titration. The standard dose escalation schedule exists for a reason. Don’t rush through titration steps. If side effects are significant at a new dose, your clinician may extend time at that level before increasing.
- Eat smaller meals. Semaglutide slows gastric emptying. Large meals worsen nausea because food sits in the stomach longer.
- Avoid high-fat and fried foods. These exacerbate GI symptoms significantly.
- Stay hydrated. Especially important if experiencing diarrhea or vomiting.
- Eat bland foods when nauseated. Crackers, toast, rice, and broth are better tolerated during peak nausea periods.
For more detailed nausea management strategies, see our guide to managing nausea on semaglutide.
Ozempic vs. Wegovy side effects
Since both contain semaglutide, the side effect profile is the same. The key difference is that Wegovy titrates to 2.4 mg (vs. Ozempic’s 2.0 mg max), which may produce slightly more GI effects at the highest dose. However, the gradual titration schedule is designed to minimize this.
If you’re researching Ozempic side effects because you’re considering semaglutide for weight loss, the information applies equally to Wegovy. At PEAK, we prescribe Wegovy for weight management and manage side effects through the entire titration process.
PEAK’s approach to side effect management
At PEAK, side effect management is built into every treatment plan. Your clinician monitors your response at each dose level and adjusts the titration schedule as needed. We don’t rush through doses, and we provide specific dietary and hydration guidance to minimize GI symptoms.
If you’re experiencing side effects on Ozempic or Wegovy, or want to know what to expect before starting, schedule a consultation.
Boxed warning — thyroid C-cell tumors: GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) carry an FDA boxed warning for thyroid C-cell tumors observed in rodent studies. They are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Tell your provider immediately if you notice a lump in your neck, difficulty swallowing, or persistent hoarseness.
